In order to prevent supply bottlenecks, the production of important medicines must take place in Europe, says Karl Lauterbach. By law, the minister wants to make studies easier and speed up approval.
Federal Minister of Health Karl Lauterbach wants to promote the research and production of drugs and medical devices in Germany with a new law. This should come by the end of the year, said the SPD politician of the ARD on the sidelines of the meeting of the G20 health ministers in the Indian city of Gandhinagar in the state of Gujarat. It should be possible to conduct drug studies in Germany more easily and then to approve drugs more quickly.
According to Lauterbach, Germany as a research location has gradually lost its attractiveness over the past ten years. “We have scaled back in drug research, we have scaled back in the approval of new drugs.”
The minister emphasized that the G20 host country India is an important location for the production and research of medicines. Products are also available here that cannot yet be manufactured in Germany at comparable costs. In addition, India is an important strategic partner and they want to expand the cooperation. Nevertheless, the production of important medicines, for example for cancer treatment, must take place in Europe in order to prevent supply bottlenecks.
Source: Stern
I have been working in the news industry for over 6 years, first as a reporter and now as an editor. I have covered politics extensively, and my work has appeared in major newspapers and online news outlets around the world. In addition to my writing, I also contribute regularly to 24 Hours World.
